Reports Q4 revenue $802,000, consensus $830,000. "We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome, and we anticipate initial data read-outs from both programs this year," said Albert Seymour, president and CEO of Homology Medicines. "Dosing of the first patient in the pheEDIT trial for PKU marked a key milestone for Homology, and the forthcoming data will represent the first gene editing data in PKU patients. We believe the continued interest in the juMPStart trial for Hunter syndrome underscores the impact a one-time gene therapy with potential to address both the peripheral and CNS disease manifestations could have for patients and their loved ones."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FIXX:
- Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
- Homology Medicines announces promotion of Jordan to CMO
- Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
- Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
- Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting